Clinical trialObservationalRecruiting
Taiwan Cancer Moonshot Project
Taiwan Cancer Moonshot Project: 1. Next-generation Pathway of Taiwan Cancer Precision Medicine (Subjective Aim 1- Taiwan Cancer Moonshot Project); 2. Development of Novel Treatments for Major Diseases (Subproject 5 - Multiomic Big Data-based Intelligent Navigation System for Precision Oncology)
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 21 February 2022
- Expected end
- 31 December 2035
- Enrollment
- 4,190 participants
- Sites
- 1
- Primary outcomes
- Collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 20 July 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform.
Detailed description public domain (ClinicalTrials.gov)
Multiomic integrative analysis is an effective strategy to facilitate the investigation of molecular mechanism, cause, and early intervention of specific diseases. Gastric cancer is specifically chosen for our research target to decrease its incidence and improve survival. To increase precision diagnosis, prognosis and precision therapy, patients from Taiwan are selected as cohort subjects. The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform. Genome, transcriptome, genomic methylation, proteomics, and post-translational modification will be used to construct a map for determine the in-depth carcinogenesis of gastric cancer and strategies for cancer early diagnosis, prevention, and targeted treatments.